Related Experiment Video
Updated: Jul 15, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report
Alessandro Sciarra1, Ana Maria Autran Gomez, Alessandro Gentilucci
1Department of Urology, University of Rome, Italy. sciarrajr@hotmail.com
Abstract:
A 69-yr-old man with bilateral and metastatic renal cell carcinoma developed progressive disease after interleukin-2 and interferon therapy. He was submitted to radical left nephrectomy, right nephron-sparing surgery, and bone metastasis removal, followed by therapy with sorafenib. At 12-mo follow-up there was a significant improvement in patient performance status and no evidence of clinical progression.
Related Concept Videos
Treatment Resistent Cancers
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

